InDex Pharmaceuticals has entered into an agreement to carry out a so-called reverse merger with Flerie, whereby Flerie will become a wholly-owned subsidiary of InDex Pharmaceuticals and Flerie’s shareholders will initially hold approximately 92 per cent of the shares in InDex Pharmaceuticals. In connection with the transaction, the company will carry out an uplisting from Nasdaq First North Growth Market to Nasdaq Stockholm and raise approximately SEK 520 million in a directed share issue.
Flerie is an active and global long-term life science investor, focusing predominantly on biotech and pharmaceutical investments. Flerie is valued at approximately SEK 3,073 million in the transaction.
Flerie was advised by KANTER in the transaction.